Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome

Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5.


Combination therapy with idarubicin plus continuous-infusion, high-dose cytarabine in patients with newly diagnosed acute myelogenous leukemia resulted in an improved complete response rate over historic controls who received either (1) Adriamycin or amsacrine in combination with standard-dose cytarabine or (2) continuous-infusion, high-dose cytarabine alone or in combination with amsacrine or mitoxantrone. The complete response rate in patients with acute myelogenous leukemia was similar to that in patients with refractory anemia with excess blasts in transformation.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Drug Administration Schedule
  • Humans
  • Idarubicin / administration & dosage*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Remission Induction
  • Survival Rate


  • Cytarabine
  • Idarubicin